Literature DB >> 21615753

Comparison of the oral bioavailability and tissue disposition of monensin and salinomycin in chickens and turkeys.

J Henri1, R Maurice, G Postollec, E Dubreil-Cheneau, B Roudaut, M Laurentie, P Sanders.   

Abstract

The current study describes the pharmacokinetic parameters of two carboxylic polyether ionophores: monensin in turkeys and salinomycin in chickens. These data can be used to understand and predict the occurrence of undesirable residues of coccidiostats in edible tissues of these animal species. Special attention is paid to the distribution of residues between the different edible tissues during and at the end of the treatment period. For the bioavailability studies, monensin was administered to turkeys intravenously, in the left wing vein, at a dose of 0.4 mg /kg and orally at a dose of 20 mg /kg. Salinomycin was administered to chickens intravenously, in the left wing vein, at a dose of 0.25 mg /kg and orally at a dose of 2.5 mg /kg. Residue studies were carried out with supplemented feed at the rate of 100 mg /kg of feed for monensin in turkeys and 70 mg /kg for salinomycin in chickens, respectively. Coccidiostats had a low bioavailability in poultry (around 30% for monensin in chickens, around 1% for monensin in turkeys and around 15% for salinomycin in chickens). Monensin in chickens had a longer terminal half-life (between 3.07 and 5.55 h) than both monensin in turkeys (between 1.36 and 1.55 h) and salinomycin in chickens (between 1.33 and 1.79 h). The tissue /plasma partition coefficients showed a higher affinity of both monensin and salinomycin for fat, followed by liver and muscle tissue. The depletion data showed a fairly rapid elimination of coccidiostats in all the tissues after cessation of treatment. According to the results of depletion studies, a withdrawal period of 1 day seems sufficient to avoid undesirable exposure of consumers.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21615753     DOI: 10.1111/j.1365-2885.2011.01285.x

Source DB:  PubMed          Journal:  J Vet Pharmacol Ther        ISSN: 0140-7783            Impact factor:   1.786


  5 in total

1.  Survival After Severe Rhabdomyolysis Following Monensin Ingestion.

Authors:  Michela Blain; Alexander Garrard; Robert Poppenga; Betty Chen; Matthew Valento; Melissa Halliday Gittinger
Journal:  J Med Toxicol       Date:  2017-05-17

2.  Specific targeting of neurotoxic side effects and pharmacological profile of the novel cancer stem cell drug salinomycin in mice.

Authors:  Wolfgang Boehmerle; Hanna Muenzfeld; Andreas Springer; Petra Huehnchen; Matthias Endres
Journal:  J Mol Med (Berl)       Date:  2014-04-27       Impact factor: 4.599

3.  Salinomycin, a polyether ionophoric antibiotic, inhibits adipogenesis.

Authors:  Maria Szkudlarek-Mikho; Rudel A Saunders; Sook Fan Yap; Yun Fong Ngeow; Khew-Voon Chin
Journal:  Biochem Biophys Res Commun       Date:  2012-10-31       Impact factor: 3.575

Review 4.  Salinomycin: a novel anti-cancer agent with known anti-coccidial activities.

Authors:  Shuang Zhou; Fengfei Wang; Eric T Wong; Ekokobe Fonkem; Tze-Chen Hsieh; Joseph M Wu; Erxi Wu
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

5.  Effects of salinomycin and ethanamizuril on the three microbial communities in vivo and in vitro.

Authors:  Xiaolei Cheng; Haihong Zheng; Chunmei Wang; Xiaoyang Wang; Chenzhong Fei; Wen Zhou; Keyu Zhang
Journal:  Front Microbiol       Date:  2022-08-12       Impact factor: 6.064

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.